TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models

Reuters01-06

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Preclinical Success of TTX-MC138 in Glioblastoma Models

TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56569) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601976228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601976228","market":"fut","top_or_hot":-1,"title":"TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Preclinical Success of TTX-MC138 in Glioblastoma Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56569) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Preclinical Success of TTX-MC138 in Glioblastoma Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56569) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL2kDv9H:1","article_id":"2601976228","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601976228","pubTimestamp":1767704568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme . The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative art","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","RNAZ":"TransCode Therapeutics  Inc.","BK4139":"生物科技"},"translate_title":"TransCode Therapeutics报告TTX-MC138在胶质母细胞瘤模型中的临床前成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":0.9},"content_text":"TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models\n    \n\n        TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56569) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601976228","isCrawlerRequest":true}